Dr. Reddy’s, Divis’ units conclude U.S. FDA inspection sans observations

A manufacturing installation each of drugmakers Dr. Reddy’s Laboratories and Divi’s Laboratories successful Andhra Pradesh and Telangana respectively has concluded inspection by the U.S. Food and Drug Administration (U.S. FDA) without immoderate observations.

The progressive pharmaceutical constituent (API) installation (CTO-SEZ) of Dr. Reddy’s successful Srikakulam was inspected betwixt November 10 and November 14, 2025. It was a GMP inspection and concluded with zero observations, the institution said successful a filing connected Friday. Dr. Reddy’s shares closed little than 1% little astatine ₹1,244.95 each connected the BSE.

In a filing connected the inspection of its unit, Divi’s Laboratories said the Unit-I installation located successful Yadadri Bhuvanagiri territory of Telangana was inspected by U.S. FDA from November 10-14. The inspection was a wide cGMP inspection and concluded with nary Form 483 observations. The company’s shares closed 1.19% little astatine ₹6,511.40 each.